Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) - Global Forecast to 2026

世界のエソテリック検査(特殊検査)市場予測:種類別、技術別、エンドユーザー別

◆タイトル:Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) - Global Forecast to 2026
◆商品コード:MD5930
◆調査・発行会社:MarketsandMarkets
◆発行日:2021年6月25日
◆ページ数:240
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社はエソテリック検査(特殊検査)の世界市場規模が2021年210億ドルから2026年363億ドルまで、年平均11.6%成長すると予想しています。本調査レポートでは、世界のエソテリック検査(特殊検査)市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別(感染症検査、内分泌検査、腫瘍検査、遺伝子検査、毒物検査、その他)分析、技術別(化学発光イムノアッセイ、ELISA、質量分析、リアルタイムPCR、DNAシークエンシング、その他)分析、エンドユーザー別(独立・参照実験室、病院実験室)分析、地域別分析、競争状況、企業情報などをまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・エソテリック検査(特殊検査)の世界市場規模:種類別(感染症検査、内分泌検査、腫瘍検査、遺伝子検査、毒物検査、その他)
・エソテリック検査(特殊検査)の世界市場規模:技術別(化学発光イムノアッセイ、ELISA、質量分析、リアルタイムPCR、DNAシークエンシング、その他)
・エソテリック検査(特殊検査)の世界市場規模:エンドユーザー別(独立・参照実験室、病院実験室)
・エソテリック検査(特殊検査)の世界市場規模:地域別
・競争状況
・企業情報

“The global esoteric testing market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period.”
Market growth is largely driven by the rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and advancements in the personalized medicine. Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market. In contrast, inadequate reimbursements of the esoteric test may restrict market growth to a certain extent. The esoteric testing market is segmented based on type, technology, end user and region.

“Infectious disease testing segment is expected to dominate the market during the forecast period and the genetic testing segment is also expected to grow at the highest CAGR during the forecast period.”
Based on product, the esoteric testing market is segmented into infectious disease testing, endocrinology testing, oncology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing. Infectious disease testing segment accounted the largest share of the esoteric testing market. The largest share of the segment is attributed to the increasing incidence of infectious diseases, technological innovations in molecular diagnostics, and improving healthcare infrastructure in developing nations. The genetic testing segment is expected to register the highest CAGR during the forecast period. The fastest growth of the genetic testing segment is attributed to the advancements in the sequencing technologies such as NGS and increasing awareness.

“CLIA segment to dominate the market during the forecast period.”
Based on technology, esoteric testing market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), mass spectrometry, real-time PCR, flow cytometry, DNA sequencing, and other technologies. CLIA accounted for the largest share of the esoteric testing market in 2020. The large share of this segment can be attributed to its advantages over other testing methods, such as high-performance levels, low detection limits, higher specificity, high signal intensity, and good precision.

“Independent & reference laboratories segment to dominate the market during the forecast period.”
Based on end user, the esoteric testing market is segmented into independent & reference laboratories and hospital-based laboratories. Independent & reference laboratories account for the largest share of the esoteric testing market. The largest share is attributed to the high testing volumes. In addition, the ongoing automation, and digitalization of diagnostic laboratories, growing number of accredited laboratories, significant reimbursement coverage, and the competitive benefits offered by these providers are pushing the growth of the segment.

“North America will dominate the market during the forecast period.”
Geographically, the esoteric testing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the esoteric testing market. The large share of the North American market can be attributed to the increasing per capita healthcare expenditure, presence of the leading market players, increasing use of rapid diagnostics, expanding geriatric population, and advancing precision medicine in the region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 48%, Tier 2: 40%, and Tier 3: 12%
• By Designation – C-level: 26%, D-level: 30%, and Others: 44%
• By Region – North America: 34%, Europe: 26%, Asia Pacific: 23%, and Rest of the World: 17%

List of Companies Profiled in the Report
• Labcorp (US)
• Quest Diagnostics (US)
• OPKO Health (US)
• H.U. Group Holdings, Inc. (Japan)
• Healius Limited (Australia)
• Sonic Healthcare (Australia)
• Mayo Foundation for Medical Education and Research (MFMER, US)
• Eurofins Scientific (Luxembourg)
• Stanford Clinical Pathology (US)
• Foundation Medicine (US)
• Kindstar Global (Beijing) Technology, Inc. (China)
• ARUP Laboratories (US)
• Georgia Esoteric & Molecular Laboratory, LLC (US)
• Thyrocare Technologies Ltd. (India)
• ACM Global Laboratories (US)
• BioAgilytix Labs (US)
• National Medical Services Inc. (NMS) (US)
• Baylor Esoteric and Molecular Laboratory (US)
• Cerba Xpert (Belgium)
• HealthQuest Esoterics (US)
• BUHLMANN Diagnostics Corp (BDC, US)
• BP Diagnostic Centre SDN BHD (Malaysia)
• Flow Health (US)
• Leo Labs, Inc. (India).

Research Coverage:
This report provides a detailed picture of the global esoteric testing market. It aims at estimating the size and future growth potential of the market across different segments, such as type, technology, end user and region. The report also analyzes factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total esoteric testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on esoteric testing services offered by the top 24 players in the esoteric testing market. The report analyses the esoteric testing market by type, technology, end user and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various esoteric testing services across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the esoteric testing market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the esoteric testing market.

【レポートの目次】

1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY 28
1.3 MARKET SEGMENTATION 29
1.3.1 MARKETS COVERED 29
FIGURE 1 ESOTERIC TESTING MARKET SEGMENTATION 29
1.3.2 YEARS CONSIDERED FOR THE STUDY 30
1.4 CURRENCY 30
1.5 STAKEHOLDERS 30
1.6 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 2 ESOTERIC TESTING MARKET: RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 33
2.1.1.1 Key data from secondary sources 33
2.1.2 PRIMARY DATA 34
FIGURE 3 PRIMARY SOURCES 34
2.1.2.1 Key data from primary sources 35
2.1.2.2 Key industry insights 36
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 36
2.2 MARKET SIZE ESTIMATION 37
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP
APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF ESOTERIC TESTING SERVICES 38
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
FIGURE 7 TOP-DOWN APPROACH 39
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 40
2.3.1 SECONDARY DATA 40
2.3.2 PRIMARY DATA 41
FIGURE 8 DATA TRIANGULATION METHODOLOGY 42
2.4 MARKET SHARE ANALYSIS 43
2.5 ASSUMPTIONS FOR THE STUDY 43
2.5.1 COVID-19-SPECIFIC ASSUMPTIONS 44
2.6 LIMITATIONS 44
2.7 RISK ASSESSMENT 45
TABLE 2 RISK ASSESSMENT 45
2.8 COVID-19 ECONOMIC ASSESSMENT 45
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 45
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 46
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 47
3 EXECUTIVE SUMMARY 48
FIGURE 11 ESOTERIC TESTING MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION) 48
FIGURE 12 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2021 VS.
2026 (USD BILLION) 49
FIGURE 13 ESOTERIC TESTING MARKET, BY END USER, 2021 VS. 2026 (USD BILLION) 49
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE ESOTERIC TESTING MARKET 50
4 PREMIUM INSIGHTS 51
4.1 ESOTERIC TESTING MARKET OVERVIEW 51
FIGURE 15 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 51
4.2 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY AND COUNTRY (2020) 52
FIGURE 16 ELISA SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MARKET IN 2020 52
4.3 ESOTERIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
FIGURE 17 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE ESOTERIC TESTING MARKET FROM 2021 TO 2026 53
4.4 ESOTERIC TESTING MARKET: REGIONAL MIX (2021–2026) 54
FIGURE 18 APAC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD 54
4.5 ESOTERIC TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS 54
FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
FIGURE 20 ESOTERIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
5.2.1 DRIVERS 56
5.2.1.1 Growing geriatric population and the increasing prevalence of chronic and infectious diseases 56
FIGURE 21 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 56
FIGURE 22 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION) 57
TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 57
FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 58
TABLE 4 ESOTERIC TESTS INDICATED FOR CHRONIC AND INFECTIOUS DISEASES 58
5.2.1.2 Increasing use of esoteric DNA sequencing technologies in precision medicine and the early diagnosis of cancer 59
5.2.1.3 Advancements in esoteric tests for personalized medicine 60
5.2.1.4 Increasing research funding for precision medicine, genetic analysis, and personalized medicine 60
5.2.1.5 Growing number of collaborations in the esoteric testing market 61
5.2.2 RESTRAINTS 61
5.2.2.1 Inadequate reimbursement 61
5.2.3 OPPORTUNITIES 61
5.2.3.1 Emerging technologies in esoteric testing 61
5.2.3.2 Growth opportunities in emerging economies 62
5.2.4 CHALLENGES 63
5.2.4.1 Dearth of skilled professionals 63
5.3 COVID-19 IMPACT ANALYSIS 63
5.3.1 COVID-19 HEALTH ASSESSMENT 63
FIGURE 24 COVID-19 GLOBAL PROPAGATION 64
5.4 IMPACT OF COVID-19 ON THE ESOTERIC TESTING MARKET 64
FIGURE 25 KEY PLAYERS: REVENUE IMPACT 65
5.5 REGULATORY OVERVIEW 66
TABLE 5 STRINGENCY OF REGULATIONS FOR CLINICAL LABORATORY ACCREDITATION, BY COUNTRY 66
5.5.1 NORTH AMERICA 66
5.5.1.1 US 66
5.5.1.2 Canada 66
5.5.2 EUROPE 67
TABLE 6 ACCREDITATION BODIES IN EUROPE 67
5.5.3 ASIA PACIFIC 68
5.5.3.1 Japan 68
5.5.3.2 India 68
5.5.3.3 China 68
5.6 TECHNOLOGY ANALYSIS 68
TABLE 7 KEY PLAYERS OFFERING ESOTERIC TESTS WITH ADVANCED TECHNOLOGIES 70
5.7 AVERAGE SELLING PRICE TREND 71
TABLE 8 AVERAGE SELLING PRICE OF ESOTERIC TESTS, 2021 71
5.8 PATENT ANALYSIS 71
FIGURE 26 LIST OF MAJOR PATENTS FOR THE ESOTERIC TESTING 72
FIGURE 27 REGIONAL ANALYSIS OF PATENTS GRANTED FOR THE ESOTERIC TESTING MARKET, 2015-2020 73
TABLE 9 INDICATIVE LIST OF ESOTERIC TESTING PATENTS 73
5.9 VALUE CHAIN ANALYSIS 75
FIGURE 28 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES 76
5.10 SUPPLY CHAIN ANALYSIS 76
FIGURE 29 DIRECT DISTRIBUTION IS THE PREFERRED STRATEGY FOR PROMINENT LABORATORIES 77

5.11 ECOSYSTEM ANALYSIS OF THE ESOTERIC TESTING MARKET 78
FIGURE 30 ECOSYSTEM ANALYSIS OF THE ESOTERIC TESTING MARKET 78
5.11.1 ROLE IN THE ECOSYSTEM 78
TABLE 10 ESOTERIC TESTING MARKET: ECOSYSTEM 78
FIGURE 31 KEY PLAYERS IN THE ESOTERIC TESTING MARKET ECOSYSTEM 79
5.12 DISRUPTIVE TECHNOLOGIES IN THE MARKET 79
FIGURE 32 DISRUPTIVE TECHNOLOGIES IN THE ESOTERIC TESTING MARKET 80
5.13 PORTER’S FIVE FORCES ANALYSIS 80
TABLE 11 HIGH FRAGMENTATION IN THE MARKET TO RESTRICT THE ENTRY OF NEW PLAYERS 80
5.13.1 INTENSITY OF COMPETITIVE RIVALRY 81
5.13.2 BARGAINING POWER OF SUPPLIERS 81
5.13.3 BARGAINING POWER OF BUYERS 81
5.13.4 THREAT OF SUBSTITUTES 81
5.13.5 THREAT OF NEW ENTRANTS 81
6 ESOTERIC TESTING MARKET, BY TYPE 82
6.1 INTRODUCTION 83
TABLE 12 ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 83
6.2 INFECTIOUS DISEASE TESTING 84
6.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 84
TABLE 13 EXAMPLES OF ESOTERIC TESTS FOR INFECTIOUS DISEASES 84
TABLE 14 ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY REGION,
2018–2026 (USD MILLION) 85
6.3 ENDOCRINOLOGY TESTING 86
6.3.1 INCREASING INCIDENCE OF DIABETES TO DRIVE THE ADOPTION
OF ESOTERIC TESTS 86
TABLE 15 ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY REGION,
2018–2026 (USD MILLION) 86
6.4 ONCOLOGY TESTING 87
6.4.1 RISING PREVALENCE OF CANCER TO DRIVE THE
MARKET FOR ESOTERIC TESTING 87
TABLE 16 GLOBAL INCIDENCE OF CANCER IN MEN, 2020 87
TABLE 17 GLOBAL INCIDENCE OF CANCER IN WOMEN, 2020 87
TABLE 18 EXAMPLES OF ESOTERIC TESTS FOR THE DIAGNOSIS OF CANCER 88
TABLE 19 ESOTERIC ONCOLOGY TESTING MARKET, BY REGION,
2018–2026 (USD MILLION) 89
6.5 GENETIC TESTING 89
6.5.1 ADVANCEMENTS IN GENOMICS AND PROTEOMICS TO SUPPORT MARKET GROWTH 89
TABLE 20 ESOTERIC GENETIC TESTING MARKET, BY REGION,
2018–2026 (USD MILLION) 90
6.6 TOXICOLOGY TESTING 90
6.6.1 INCREASING CASES OF DRUG ABUSE AND ILLICIT DRUG CONSUMPTION HAVE INCREASED THE DEMAND FOR ESOTERIC TESTING 90
TABLE 21 ESOTERIC TOXICOLOGY TESTING MARKET, BY REGION,
2018–2026 (USD MILLION) 91
6.7 IMMUNOLOGY TESTING 91
6.7.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH 91
TABLE 22 INCIDENCE OF AUTOIMMUNE DISEASES, BY TYPE 91
TABLE 23 EXAMPLES OF ESOTERIC TESTS AVAILABLE FOR IMMUNOLOGY TESTING 92
TABLE 24 ESOTERIC IMMUNOLOGY TESTING MARKET, BY REGION,
2018–2026 (USD MILLION) 92
6.8 NEUROLOGY TESTING 93
6.8.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDER TO DRIVE MARKET GROWTH 93
TABLE 25 EXAMPLES OF ESOTERIC TESTS FOR NEUROLOGICAL DISORDERS 93
TABLE 26 ESOTERIC NEUROLOGY TESTING MARKET, BY REGION,
2018–2026 (USD MILLION) 94
6.9 OTHER TESTING 94
TABLE 27 OTHER ESOTERIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION) 95
7 ESOTERIC TESTING MARKET, BY TECHNOLOGY 96
7.1 INTRODUCTION 97
TABLE 28 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018–2026 (USD MILLION) 97
7.2 CHEMILUMINESCENCE IMMUNOASSAY 97
7.2.1 RISING GERIATRIC POPULATION TO AID MARKET GROWTH 97
TABLE 29 ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY,
BY REGION, 2018–2026 (USD MILLION) 98
7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY 98
7.3.1 GROWING NUMBER OF DRUG DISCOVERY ACTIVITIES TO DRIVE MARKET GROWTH 98
TABLE 30 EXAMPLES OF ESOTERIC ELISA TESTS 98
TABLE 31 ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018–2026 (USD MILLION) 99
7.4 MASS SPECTROMETRY 99
7.4.1 MASS SPECTROMETRY IS USED IN ENDOCRINE TESTING AND INFECTIOUS DISEASE DIAGNOSIS 99
TABLE 32 EXAMPLES OF ESOTERIC MASS SPECTROMETRY TESTS 99
TABLE 33 ESOTERIC TESTING MARKET FOR MASS SPECTROMETRY, BY REGION,
2018–2026 (USD MILLION) 100
7.5 REAL-TIME PCR 101
7.5.1 INCREASING USE OF QPCR FOR VARIOUS DIAGNOSTIC AND RESEARCH PURPOSES TO DRIVE MARKET GROWTH 101
TABLE 34 ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY REGION,
2018–2026 (USD MILLION) 101
7.6 DNA SEQUENCING 101
7.6.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO AID MARKET GROWTH 101
TABLE 35 EXAMPLES OF ESOTERIC TESTS FOR DNA SEQUENCING 102
TABLE 36 ESOTERIC TESTING MARKET FOR DNA SEQUENCING, BY REGION,
2018–2026 (USD MILLION) 103
7.7 FLOW CYTOMETRY 103
7.7.1 RISING PREVALENCE OF CANCER, HIV, AND HEMATOLOGIC MALIGNANCIES TO DRIVE MARKET GROWTH 103
TABLE 37 ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY REGION,
2018–2026 (USD MILLION) 104
7.8 OTHER TECHNOLOGIES 104
TABLE 38 ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2018–2026 (USD MILLION) 105
8 ESOTERIC TESTING MARKET, BY END USER 106
8.1 INTRODUCTION 107
TABLE 39 ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION) 107
8.2 INDEPENDENT & REFERENCE LABORATORIES 107
8.2.1 INDEPENDENT & REFERENCE LABORATORIES ARE THE LARGEST END USERS OF ESOTERIC TESTS 107
TABLE 40 ESOTERIC TESTING MARKET FOR INDEPENDENT & REFERENCE LABORATORIES, BY REGION, 2018–2026 (USD MILLION) 108
8.3 HOSPITAL-BASED LABORATORIES 108
8.3.1 HOSPITAL-BASED LABORATORIES ARE MORE ACCESSIBLE AND OFFER TEST RESULTS IN A SHORTER TIME PERIOD 108
TABLE 41 ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES,
BY REGION, 2018–2026 (USD MILLION) 109
9 ESOTERIC TESTING MARKET, BY REGION 110
9.1 INTRODUCTION 111
TABLE 42 ESOTERIC TESTING MARKET, BY REGION, 2018–2026 (USD MILLION) 111
9.2 NORTH AMERICA 112
FIGURE 33 NORTH AMERICA: ESOTERIC TESTING MARKET SNAPSHOT 113
TABLE 43 NORTH AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY,
2018–2026 (USD MILLION) 114
TABLE 44 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TYPE,
2018–2026 (USD MILLION) 114
TABLE 45 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 115
TABLE 46 NORTH AMERICA: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 115
9.2.1 US 115
9.2.1.1 The US dominates the North American esoteric testing market 115
TABLE 47 US: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 116
TABLE 48 US: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 116
TABLE 49 US: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 117
TABLE 50 US: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION) 117
9.2.2 CANADA 117
9.2.2.1 Lack of proper reimbursements for diagnostic tests to hamper the market growth 117
TABLE 51 CANADA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 118
TABLE 52 CANADA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 119
TABLE 53 CANADA: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 119
9.3 EUROPE 119
TABLE 54 EUROPE: ESOTERIC TESTING MARKET, BY COUNTRY,
2018–2026 (USD MILLION) 120
TABLE 55 EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 121
TABLE 56 EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 121
TABLE 57 EUROPE: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 122
9.3.1 GERMANY 122
9.3.1.1 Germany held the largest share of the European esoteric testing market in 2020; this trend will continue in the forecast period 122
TABLE 58 GERMANY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 122
TABLE 59 GERMANY: ESOTERIC TESTING MARKET, BY TYPE,
2018–2026 (USD MILLION) 123
TABLE 60 GERMANY: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 123
TABLE 61 GERMANY: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 124
9.3.2 FRANCE 124
9.3.2.1 Rising demand for early disease diagnosis to drive market growth 124
TABLE 62 FRANCE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 124
TABLE 63 FRANCE: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 125
TABLE 64 FRANCE: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 125
9.3.3 ITALY 125
9.3.3.1 Rapidly growing geriatric population in Italy to favor market growth 125
TABLE 65 ITALY: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 126
TABLE 66 ITALY: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 126
TABLE 67 ITALY: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 127
9.3.4 UK 127
9.3.4.1 The UK is the fastest-growing market for esoteric testing in Europe due to the favorable investment scenario in the country 127
TABLE 68 UK: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 128
TABLE 69 UK: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 128
TABLE 70 UK: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION) 129
9.3.5 SPAIN 129
9.3.5.1 High burden of chronic and infectious diseases in the country to drive the adoption of esoteric tests 129
TABLE 71 SPAIN: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 129
TABLE 72 SPAIN: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 130
TABLE 73 SPAIN: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 130
9.3.6 REST OF EUROPE 130
TABLE 74 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025 131
TABLE 75 ROE: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025 131
TABLE 76 ROE: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 131
TABLE 77 ROE: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 132
TABLE 78 ROE: ESOTERIC TESTING MARKET, BY END USER, 2018–2026 (USD MILLION) 132
9.4 ASIA PACIFIC 132
FIGURE 34 ASIA PACIFIC: ESOTERIC TESTING MARKET SNAPSHOT 133
TABLE 79 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY COUNTRY,
2018–2026 (USD MILLION) 134
TABLE 80 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE,
2018–2026 (USD MILLION) 134
TABLE 81 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 135
TABLE 82 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 135
9.4.1 JAPAN 135
9.4.1.1 Presence of a well-developed healthcare system to favor market growth in Japan 135
TABLE 83 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 136
TABLE 84 JAPAN: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 136
TABLE 85 JAPAN: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 137
TABLE 86 JAPAN: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 137
9.4.2 CHINA 137
9.4.2.1 China to register the highest growth rate in the esoteric testing market during the forecast period 137
TABLE 87 CHINA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 138
TABLE 88 CHINA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 139
TABLE 89 CHINA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 139
TABLE 90 CHINA: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 139
9.4.3 INDIA 140
9.4.3.1 Improving healthcare system in the country to support market growth 140
TABLE 91 INDIA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 140
TABLE 92 INDIA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 141
TABLE 93 INDIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 141
TABLE 94 INDIA: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 141
9.4.4 REST OF ASIA PACIFIC 142
TABLE 95 ROAPAC: CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2040 142
TABLE 96 ROAPAC: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 143
TABLE 97 ROAPAC: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 143
TABLE 98 ROAPAC: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 144
9.5 LATIN AMERICA 144
TABLE 99 LATIN AMERICA: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025 144
TABLE 100 LATIN AMERICA: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025 145
TABLE 101 LATIN AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY,
2018–2026 (USD MILLION) 145
TABLE 102 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE,
2018–2026 (USD MILLION) 146
TABLE 103 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 146
TABLE 104 LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 147
9.5.1 BRAZIL 147
9.5.1.1 Brazil is the largest market for esoteric testing in Latin America 147
TABLE 105 BRAZIL: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 148
TABLE 106 BRAZIL: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 148
TABLE 107 BRAZIL: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 149
9.5.2 MEXICO 149
9.5.2.1 Growth in the private healthcare sector to propel market growth 149
TABLE 108 MEXICO: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 149
TABLE 109 MEXICO: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 150
TABLE 110 MEXICO: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 150
9.5.3 REST OF LATIN AMERICA 150
TABLE 111 ROLATAM: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 151
TABLE 112 ROLATAM: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 151
TABLE 113 ROLATAM: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 152
9.6 MIDDLE EAST & AFRICA 152
9.6.1 IMPROVEMENTS IN THE HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET FOR ESOTERIC TESTING IN THE MEA 152
TABLE 114 AFRICA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 152
TABLE 115 MEA: ESOTERIC TESTING MARKET, BY TYPE, 2018–2026 (USD MILLION) 153
TABLE 116 MEA: ESOTERIC TESTING MARKET, BY TECHNOLOGY,
2018–2026 (USD MILLION) 153
TABLE 117 MEA: ESOTERIC TESTING MARKET, BY END USER,
2018–2026 (USD MILLION) 154
10 COMPETITIVE LANDSCAPE 155
10.1 OVERVIEW 155
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 155
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY ESOTERIC TESTING LABORATORIES 155
10.3 REVENUE ANALYSIS 157
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN THE ESOTERIC TESTING MARKET 157
10.4 MARKET SHARE ANALYSIS 157
FIGURE 36 ESOTERIC TESTING MARKET SHARE ANALYSIS, 2020 158
TABLE 118 ESOTERIC TESTING MARKET: DEGREE OF COMPETITION 158
10.5 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS) 159
10.5.1 STARS 160
10.5.2 PERVASIVE PLAYERS 160
10.5.3 EMERGING LEADERS 160
10.5.4 PARTICIPANTS 160
FIGURE 37 ESOTERIC TESTING MARKET (GLOBAL): COMPANY EVALUATION
QUADRANT, 2020 161
10.6 COMPANY EVALUATION QUADRANT (SMES/START-UPS) 162
10.6.1 PROGRESSIVE COMPANIES 162
10.6.2 STARTING BLOCKS 162
10.6.3 RESPONSIVE COMPANIES 162
10.6.4 DYNAMIC COMPANIES 162
FIGURE 38 ESOTERIC TESTING MARKET: COMPANY EVALUATION QUADRANT
FOR START-UPS/SMES, 2020 163
10.7 COMPETITIVE BENCHMARKING 163
10.7.1 COMPANY TECHNOLOGY FOOTPRINT 164
10.7.2 COMPANY TESTING FOOTPRINT 165
10.7.3 COMPANY REGIONAL FOOTPRINT 166
10.7.4 COMPANY FOOTPRINT 167
10.8 COMPETITIVE SCENARIO AND TRENDS 168
10.8.1 DEALS 168
TABLE 119 DEALS, JANUARY 2018-MAY 2021 168
10.8.2 SERVICE LAUNCHES & APPROVALS 169
TABLE 120 SERVICE LAUNCHES & APPROVALS, JANUARY 2018-MAY 2021 169
10.8.3 OTHER DEVELOPMENTS 169
TABLE 121 OTHER DEVELOPMENTS, JANUARY 2018-MAY 2021 170

11 COMPANY PROFILES 171
11.1 MAJOR PLAYERS 171
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 LABCORP 171
TABLE 122 LABCORP: BUSINESS OVERVIEW 171
FIGURE 39 LABCORP: COMPANY SNAPSHOT (2020) 172
11.1.2 QUEST DIAGNOSTICS 180
TABLE 123 QUEST DIAGNOSTICS: BUSINESS OVERVIEW 180
FIGURE 40 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2020) 181
11.1.3 OPKO HEALTH, INC. 185
FIGURE 41 OPKO HEALTH: COMPANY SNAPSHOT (2020) 186
11.1.4 H.U. GROUP HOLDINGS, INC. 191
TABLE 124 H.U. GROUP HOLDINGS, INC.: BUSINESS OVERVIEW 191
FIGURE 42 H.U. GROUP HOLDINGS, INC.: COMPANY SNAPSHOT (2019) 191
11.1.5 HEALIUS LIMITED 193
TABLE 125 HEALIUS LIMITED: BUSINESS OVERVIEW 193
FIGURE 43 HEALIUS LIMITED: COMPANY SNAPSHOT (2020) 193
11.1.6 SONIC HEALTHCARE LIMITED 196
TABLE 126 SONIC HEALTHCARE LIMITED: BUSINESS OVERVIEW 196
FIGURE 44 SONIC HEALTHCARE LIMITED: COMPANY SNAPSHOT (2020) 197
11.1.7 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER) 199
FIGURE 45 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: COMPANY SNAPSHOT (2020) 199
11.1.8 EUROFINS SCIENTIFIC 201
TABLE 127 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 201
FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020) 202
11.1.9 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY) 204
TABLE 128 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY): BUSINESS OVERVIEW 204
11.1.10 FOUNDATION MEDICINE, INC. 206
TABLE 129 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW 206
11.1.11 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC. 210
TABLE 130 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.: BUSINESS OVERVIEW 210
11.1.12 ARUP LABORATORIES 213
TABLE 131 ARUP LABORATORIES: BUSINESS OVERVIEW 213
11.1.13 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC 217
TABLE 132 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: BUSINESS OVERVIEW 217
11.1.14 THYROCARE TECHNOLOGIES LIMITED 219
TABLE 133 THYROCARE TECHNOLOGIES LIMITED: BUSINESS OVERVIEW 219
FIGURE 47 THYROCARE TECHNOLOGIES LIMITED: COMPANY SNAPSHOT (2020) 219
11.1.15 ACM GLOBAL LABORATORIES 221
TABLE 134 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW 221
11.2 OTHER PLAYERS 223
11.2.1 BIOAGILYTIX LABS 223
11.2.2 BP DIAGNOSTIC CENTRE SDN. BHD. 226
11.2.3 NMS LAB 228
11.2.4 BAYLOR ESOTERIC AND MOLECULAR LABORATORY 228
11.2.5 HEALTHQUEST ESOTERICS 230
11.2.6 CERBA XPERT 231
11.2.7 BUHLMANN DIAGNOSTICS CORP 232
11.2.8 LEO LABS, INC. 233
11.2.9 FLOW HEALTH 234
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 235
12.1 INSIGHTS FROM INDUSTRY EXPERTS 235
12.2 DISCUSSION GUIDE 236
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 240
12.4 AVAILABLE CUSTOMIZATIONS 242
12.5 RELATED REPORTS 242
12.6 AUTHOR DETAILS 244



★調査レポート[世界のエソテリック検査(特殊検査)市場予測:種類別、技術別、エンドユーザー別] ( Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) - Global Forecast to 2026 / MD5930) 販売に関する免責事項
[世界のエソテリック検査(特殊検査)市場予測:種類別、技術別、エンドユーザー別] ( Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) - Global Forecast to 2026 / MD5930) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆